Bronchopulmonary Carcinoids causing Cushing Syndrome: Results from a Multicentric Study Suggesting a More Aggressive Behavior

Abstract

Objective Cushing syndrome (CS) caused by bronchopulmonary carcinoids (BCs) is a very rare entity. The aim of this study was to revisit the features of a multicenter clinical series to identify significant prognostic factors.

Methods From January 2002 to December 2013, the clinical and pathological data of 23 patients (treated in five different institutions) were retrospectively reviewed. Survival analysis was performed to explore the relative weight of potential prognostic factors.

Results Median age and male/female ratio were 48 years and 14/9, respectively. Most (> 80%) of the patients presented with CS-related symptoms at diagnosis. Tumor location was peripheral in 13 patients (57%) and central in 10 (43%). All patients but two (treated with chemotherapy) underwent surgical resection with curative intent. Definitive cyto/histology was indicative of typical carcinoid (TC) in 16 cases (70%) and atypical carcinoid (AC) in 7 cases (30%). A complete remission of CS was obtained in 16 cases (70%). Lymph nodal involvement was detected in 11 cases (48%), with N2 disease occurring in 7 (∼ 30% of all cases). Four patients (22%) experienced a relapse of the disease after radical surgery. Overall 5-year survival (long-term survival, LTS) was 60%, better in TCs when compared with AC (LTS: 66 v s. 48%, p = 0.28). Log-rank analysis identified ECOG performance status, cTNM and cN staging, pTNM and pN staging, persistence of CS and relapses (local p = 0.006; distant p = 0.001) as significant prognostic factors in this cohort of patients.

Conclusion BCs causing CS are characterized by a high rate of lymph–nodal involvement, a suboptimal prognosis (5-year survival = 60%, 66% in TCs) and a remarkable risk of relapse even after radical resection. Advanced stage, lymph–nodal involvement and the persisting of the CS after treatment correlate with a poor prognosis.

Keywords

lung cancer - diagnosis - pathology - tumor

Note

Presented at “22nd European Conference on General Thoracic Surgery,” Copenhagen, 15–18 June 2014.

• References

• 1 Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367 (9522) 1605-1617
• 2 Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970 (1) 134-144
• 3 Deb SJ, Nichols FC, Allen MS, Deschamps C, Cassivi SD, Pairolero PC. Pulmonary carcinoid tumors with Cushing's syndrome: an aggressive variant or not?. Ann Thorac Surg 2005; 79 (4) 1132-1136 , discussion 1132–1136
• 4 Limper AH, Carpenter PC, Scheithauer B, Staats BA. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med 1992; 117 (3) 209-214
• 5 Scanagatta P, Montresor E, Pergher S , et al. Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases. Chir Ital 2004; 56 (1) 63-70
• 6 Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol 2007; 51 (8) 1217-1225
• 7 Riggs Jr BL, Sprague RG. Association of Cushing's syndrome and neoplastic disease: observations in 232 cases of Cushing's syndrome and review of the literature. Arch Intern Med 1961; 108: 841-849
• 8 Brown WH. A case of pluriglandular syndrome (diabetes of bearded woman). Lancet 1928; ii: 1022-1023
• 9 Boddaert G, Grand B, Le Pimpec-Barthes F, Cazes A, Bertagna X, Riquet M. Bronchial carcinoid tumors causing Cushing's syndrome: more aggressive behavior and the need for early diagnosis. Ann Thorac Surg 2012; 94 (6) 1823-1829
• 10 Shrager JB, Wright CD, Wain JC, Torchiana DF, Grillo HC, Mathisen DJ. Bronchopulmonary carcinoid tumors associated with Cushing's syndrome: a more aggressive variant of typical carcinoid. J Thorac Cardiovasc Surg 1997; 114 (3) 367-375
• 11 Amer KMA, Ibrahim NBN, Forrester-Wood CP, Saad RA, Scanlon M. Lung carcinoid related Cushing's syndrome: report of three cases and review of the literature. Postgrad Med J 2001; 77 (909) 464-467
• 12 Lardinois D, De Leyn P, Van Schil P , et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006; 30 (5) 787-792
• 13 Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005; 40 (2) 90-97
• 14 Travis WD, Giroux DJ, Chansky K , et al; International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3 (11) 1213-1223
• 15 Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90 (8) 4955-4962
• 16 Davila DG, Dunn WF, Tazelaar HD, Pairolero PC. Bronchial carcinoid tumors. Mayo Clin Proc 1993; 68 (8) 795-803
• 17 Pass HI, Doppman JL, Nieman L , et al. Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg 1990; 50 (1) 52-57
• 18 Lococo F, Margaritora S, Cardillo G , et al. Prognostic factors in pulmonary carcinoid causing cushing's syndrome: a multicentre analysis. Paper presented at: 22nd European Conference on General Thoracic Surgery Abstracts, Copenaghen. June 15–18, 2014
• 19 Ejaz S, Vassilopoulou-Sellin R, Busaidy NL , et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer 2011; 117 (19) 4381-4389
• 20 Kenchaiah M, Hyer S. Cushing's Syndrome due to Ectopic ACTH from Bronchial Carcinoid: A Case Report and Review. Case Rep Endocrinol 2012; 2012: 215038
• 21 Özkan ZG, Kuyumcu S, Balköse D , et al. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors. Mol Imaging Radionucl Ther 2013; 22 (2) 49-55
• 22 Treglia G, Giovanella L, Lococo F. Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014; 41 (5) 853-855
• 23 Lococo F, Cesario A, Paci M , et al. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol 2014; 35 (9) 8369-8377
• 24 Gani LU, Gianatti EJ, Cheung AS, Jerums G, MacIsaac RJ. Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: a case report. J Med Case Reports 2011; 5: 405
• 25 Cardillo G, Sera F, Di Martino M , et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 2004; 77 (5) 1781-1785
• 26 Filosso PL, Oliaro A, Ruffini E , et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol 2013; 8 (10) 1282-1288
• 27 Grossrubatscher E, Vignati F, Dalino P , et al. Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome. J Endocrinol Invest 2005; 28 (1) 72-78
• 28 Porziella V, Cesario A, Lococo F , et al. The radioguided 111In-pentetreotide surgery in the management of ACTH-secreting bronchial carcinoid. Eur Rev Med Pharmacol Sci 2011; 15 (6) 587-591